Recent news on Glumetza

Depomed Reports First Quarter 2007 Financial Results  -  May 8, 2007
Genetic Engineering News (press release),The increase was primarily due to expenses associated with the commercialization of Glumetza, legal expenses related to the ongoing patent infringement case

Depomed to Present at the Bank of America 2007 Healthcare Conference  -  May 22, 2007
PharmaLive.com (press release),Glumetza(TM) (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is being marketed in the United

Biovail Reports First-Quarter 2007 Financial Results, Plans to ...  -  May 10, 2007
Business Wire (press release),...a decrease of 19% that primarily reflects the third-quarter 2006 write-down of intangible assets associated with Vasotec® and Glumetza™.

Depomed Files Prior Approval Supplement for 1000 mg Strength ...  -  Apr 2, 2007
PharmaLive.com (press release),Glumetza(TM) (metformin hydrochloride extended release tablets) is indicated alone or in combination with sulfonylurea or insulin as an adjunct to diet and

Depomed Asks for New Glumetza Approval  -  Apr 2, 2007
Forbes,Depomed Inc. said Monday it asked the Food and Drug Administration to approve a new 1000-milligram strength formulation of diabetes drug Glumetza.

Depomed Completes $20 Million Registered Direct Offering  -  Apr 23, 2007
Genetic Engineering News (press release),In addition, once daily Glumetza(TM) (metformin hydrochloride extended release tablets) has been approved for use in adults with type 2 diabetes and is

Depomed to Announce First Quarter 2007 Financial Results on ...  -  Apr 25, 2007
PharmaLive.com (press release),Glumetza(TM) (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is being marketed in the United

Depomed to Present at the CIBC World Markets Annual Biotechnology ...  -  Apr 4, 2007
PharmaLive.com (press release),Glumetza(TM) (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is being marketed in the United

Depomed Reports 2006 Year End Financial Results  -  Mar 14, 2007
Genetic Engineering News (press release),In addition, $526000 was in product sales of Glumetza(TM) (metformin hydrochloride extended release tablets) through King Pharmaceuticals and $109000 was

Depomed FY06 Loss Widens On Mounting Costs And Expenses - Update  -  Mar 14, 2007
Trading Markets,In addition, product sales of Glumetza through King Pharmaceuticals totaled $526000 while $109000 was attributed to royalties on sales of Glumetza in Canada

Depomed Shares Up on Analysts' Outlook  -  Mar 15, 2007
Houston Chronicle,The company is marketing Glumetza for diabetes and Proquin extended release for urinary tract infections. Gabapentin GR is in mid-phase clinical trials for

Depomed to Announce Fourth Quarter and Year End 2006 Financial ...  -  Feb 28, 2007
PharmaLive.com (press release),In addition, once daily Glumetza(TM) (metformin hydrochloride extended release tablets) has been approved for use in adults with type 2 diabetes and is

Depomed Appoints David Zenoff to Board of Directors  -  Mar 23, 2007
PharmaLive.com (press release),Glumetza(TM) (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is being marketed in the United

Biovail Reports Record Fourth Quarter, Year-End 2006 Financial Results  -  Mar 15, 2007
CNW Telbec (Communiqués de presse),In addition, upon a reassessment of the Canadian market opportunity for the product, Biovail reduced the carrying value of the Glumetza(TM) product rights

Depomed and Biovail Sign License Agreement for AcuForm(TM) Drug ...  -  Feb 12, 2007
CNW Telbec (Communiqués de presse),In addition, once daily Glumetza(TM) (metformin hydrochloride extended release tablets) has been approved for use in adults with type 2 diabetes and is

Loyalty program for diabetes patients  -  Dec 21, 2006
Colloquy.com (subscription),Patients who participate in the Glumetza Patient Loyalty Card program will receive an immediate discount of up to $20 off their required co-pay for a supply

Depomed Announces Sweeping Interim Victory in Litigation against Ivax  -  Dec 21, 2006
PharmaLive.com (press release),In addition, once daily Glumetza(TM) (metformin hydrochloride extended release tablets) has been approved for use in adults with type 2 diabetes and is

Depomed Gets Good Pretrial Decision  -  Dec 20, 2006
Houston Chronicle,Depomed sued Ivax over two patents covering its AcuForm drug delivery technology, which is used in Glumetza, an extended-release treatment of Type II

Depomed says gets favorable decision in suit against Ivax  -  Dec 20, 2006
ReutersIn a statement, Depomed said it sued Ivax for infringement on its Glumetza product. As a result of this ruling, the case is now scheduled to proceed through

Thursday's Health Winners & Losers  -  Dec 21, 2006
TheStreet.comThe patents cover a drug delivery technology used in Depomed's diabetes drug Glumetza. Shares of Accentia Biopharmaceuticals (ABPI - commentary - Cramer's

Market Report -- In Play (DEPO)  -  Dec 20, 2006
MSN MoneyDepomed's Glumetza product is covered by these patents. After comprehensive briefing and oral argument, Judge Breyer filed a Markman order rejecting all

Loyalty program for diabetes patients  -  Dec 21, 2006
Colloquy.com (subscription),Patients who participate in the Glumetza Patient Loyalty Card program will receive an immediate discount of up to $20 off their required co-pay for a supply

Depomed Announces Sweeping Interim Victory in Litigation against Ivax  -  Dec 21, 2006
PharmaLive.com (press release),In addition, once daily Glumetza(TM) (metformin hydrochloride extended release tablets) has been approved for use in adults with type 2 diabetes and is

Depomed Gets Good Pretrial Decision  -  Dec 20, 2006
Houston Chronicle,Depomed sued Ivax over two patents covering its AcuForm drug delivery technology, which is used in Glumetza, an extended-release treatment of Type II

Depomed says gets favorable decision in suit against Ivax  -  Dec 20, 2006
ReutersIn a statement, Depomed said it sued Ivax for infringement on its Glumetza product. As a result of this ruling, the case is now scheduled to proceed through

Depomed gets $30M in equity financing  -  Dec 12, 2006
BusinessWeekDepomed makes Glumetza, an extended-release diabetes drug, and ProQuin XR to treat urinary tract infections. Its Gabapentin GR is in late-stage development

Thursday's Health Winners & Losers  -  Dec 21, 2006
TheStreet.comThe patents cover a drug delivery technology used in Depomed's diabetes drug Glumetza. Shares of Accentia Biopharmaceuticals (ABPI - commentary - Cramer's

Market Report -- In Play (DEPO)  -  Dec 20, 2006
MSN MoneyDepomed's Glumetza product is covered by these patents. After comprehensive briefing and oral argument, Judge Breyer filed a Markman order rejecting all

Diabetes Drugs Compared  -  Dec 6, 2006
CBS News,Glucophage is a brand-name version of metformin, which is also sold generically and under other brand names including Glumetza, Fortamet, and Riomet.

Biovail Provides Strategy Update  -  Dec 7, 2006
CNW Telbec (Communiqués de presse),The 100-member BPC sales force currently promotes Tiazac(R) XC, Wellbutrin(R) XL, Glumetza(TM) and the Lescol(R) franchise to Canadian physicians.

Biovail Provides Strategy Update  -  Dec 6, 2006
Business Wire (press release),The 100-member BPC sales force currently promotes Tiazac® XC, Wellbutrin® XL, Glumetza™ and the Lescol® franchise to Canadian physicians.

Depomed Comments on Today’s Trading Activity  -  Dec 4, 2006
Business Wire (press release),In addition, once daily Glumetza TM (metformin hydrochloride extended release tablets) has been approved for use in adults with type 2 diabetes and is

Depomed Reports Third Quarter 2006 Financial Results  09 Nov 2006
Third quarter 2006 revenues were primarily due to amortization of license fees received in 2005 from corporate partners for ProQuin XR® and Glumetza™. ... -Business Wire (press release), King Pharmaceuticals Reports Third-Quarter 2006 Financial Results  09 Nov 2006
Importantly, we strengthened our portfolio with the launch of Glumetza™, a new generation metformin product for patients with Type II diabetes, and our ... -Business Wire (press release), Biovail Reports Third-Quarter 2006 Financial Results  09 Nov 2006
R) ER recall, increased costs related to Sarbanes-Oxley compliance, information-technology infrastructure upgrades, the recent launches of Glumetza(TM) and ... -Canada NewsWire (press release), Depomed to Announce Third Quarter 2006 Financial Results on ...  Oct 26, 2006
In addition, once daily Glumetza(TM) (metformin hydrochloride extended release tablets) has been approved for use in adults with type 2 diabetes and is ... -Genetic Engineering News (press release), King Pharma, Depomed Launch Glumetza  Sep 6, 2006
...— Drug makers King Pharmaceuticals Inc. and Depomed Inc. said Wednesday their type 2 diabetes treatment Glumetza is available on the US market. ... -Houston Chronicle

New Once-Daily Oral Diabetes Treatment Glumetza(TM) Now Available  Sep 6, 2006
...(NASDAQ: DEPO) today announced the commercial availability of Glumetza(TM) (metformin hydrochloride extended release tablets) in the United States. ... -Genetic Engineering News

Depomed to Present at the UBS Global Life Sciences Conference  Sep 20, 2006
In addition, once daily Glumetza(TM) (metformin hydrochloride extended release tablets) has been approved for use in adults with type 2 diabetes and is ... -Business Wire

Patheon breaks into drug delivery  Aug 29, 2006
XR, a once-daily, extended-release formulation of ciprofloxacin hydrochloride for the treatment of uncomplicated urinary tract infections, and Glumetza, a once ... -In-PharmaTechnologist.com

STARWATCH CONSUMER  Sep 7, 2006
King Pharmaceuticals Inc. and Depomed Inc. said Glumetza, the type 2 diabetes drug, is now available in once-daily tablets. Glumetza ... -Kansas City Star

Depomed Gets $30M in Equity Financing  -  12 Dec 2006
Houston Chronicle,Depomed makes Glumetza, an extended-release diabetes drug, and ProQuin XR to treat urinary tract infections. Its Gabapentin GR is in late-stage development

Diabetes :: Contributing To The Fight Against Diabetes Is Only A ...  -  Nov 16, 2006
SpiritIndia,King Pharmaceuticals and Depomed market Glumetza™ (metformin hydrochloride extended release tablets), a new once-daily extended-release metformin

Contributing to the Fight against Diabetes is Only a Click Away ...  -  Nov 15, 2006
PharmaLive.com (press release),Glumetza(TM) (metformin hydrochloride extended-release tablets) is indicated alone or in combination with sulfonylurea or insulin as an adjunct to diet and

Biovail Provides Strategy Update  -  Dec 7, 2006
CNW Telbec (Communiqués de presse),The 100-member BPC sales force currently promotes Tiazac(R) XC, Wellbutrin(R) XL, Glumetza(TM) and the Lescol(R) franchise to Canadian physicians.

Diabetes Drugs Compared  -  Dec 6, 2006
CBS News,Glucophage is a brand-name version of metformin, which is also sold generically and under other brand names including Glumetza, Fortamet, and Riomet.

Biovail Provides Strategy Update  -  Dec 6, 2006
Business Wire (press release),The 100-member BPC sales force currently promotes Tiazac® XC, Wellbutrin® XL, Glumetza™ and the Lescol® franchise to Canadian physicians.

Depomed Comments on Today's Trading Activity  -  Dec 5, 2006
PharmaLive.com (press release),In addition, once daily Glumetza(TM) (metformin hydrochloride extended release tablets) has been approved for use in adults with type 2 diabetes and is

Patheon breaks into drug delivery  29 Aug 2006
XR, a once-daily, extended-release formulation of ciprofloxacin hydrochloride for the treatment of uncomplicated urinary tract infections, and Glumetza, a once ... -In-PharmaTechnologist.com

Depomed, King Pharma Prepare To Launch Glumetza, Reveals New ADA ...  Aug 23, 2006
...(KG | charts | news | PowerRating) prepare for the launch of Glumetza, a statement was issued from the American Diabetes Association or ADA and the European ... -Trading Markets

TODAY ON PHARMALIVE.COM  Aug 23, 2006
...(NASDAQ:DEPO) and King Pharmaceuticals, Inc. (NYSE:KG) announced today that as they prepare for the launch of Glumetza(TM) (metformin hydrochloride extended ... -PharmaLive.com

King Pharmaceuticals Reports Second-Quarter 2006 Financial Results  Aug 9, 2006
...a marketing strategy designed to reinvigorate demand for Altace(R). Additionally, this opportunity, coupled with the recent addition of Glumetza(TM) (metformin ... -PharmaLive.com

Depomed Reports Second Quarter 2006 Financial Results; Revenues ...  Aug 7, 2006
...of 2005 primarily as a result of product sales and license and royalty revenue for the company's two commercialized products, ProQuin(R) XR and Glumetza(TM). ... -Business Wire

Depomed posts loss of $9.9M for Q2  Aug 7, 2006
...second quarter, up from revenue of $428,000 a year ago, mostly driven by sales of its two drugs, ProQuin, for urinary tract infections and Glumetza, for Type ... -San Francisco Business Times

Depomed loss grows 34 percent in Q2 on higher expenses  Aug 7, 2006
...product sales and license and royalty revenue for the company's two commercialized products, ProQuinXR, for urinary tract infections, and Glumetza, for adult ... -San Jose Business Journal

Merck Provides Preliminary Analyses of the Completed MEDAL Program ...  Aug 24, 2006
Depomed, Inc. (NASDAQ:DEPO) and King Pharmaceuticals, Inc. (NYSE:KG) announced recently that as they prepare for the launch of Glumetza(TM) (metformin ... -Financial News USA

Depomed Gains Greater Access to Global Pharmaceutical Companies ...  Aug 7, 2006
Patheon is the contract manufacturer for Depomed's two approved products, ProQuin(R) XR and Glumetza(TM), and is therefore familiar with Depomed's patented ... -PharmaLive.com

Depomed Announces Completion of Phase I Clinical Trial With ...  Aug 15, 2006
In addition, once daily Glumetza(TM) for the treatment of Type II diabetes has been approved and is currently being marketed in Canada. ... -Business Wire

Biovail Reports Second-Quarter 2006 Financial Results; Company ...  Aug 10, 2006
...physicians. These medicines are complementary to BPC's existing product offerings, including Tiazac(R) XC and Glumetza(TM). Product ... -Genetic Engineering News



Depomed Reports First Quarter 2006 Financial Results  May 10, 2006
...in the same period of 2005 primarily as a result of license and royalty revenue for the company's two commercialized products, ProQuin(R) XR and Glumetza(TM). ... - Genetic Engineering News

DepoMed Q1 Net Loss Widens On Higher Costs And Expenses -Update  May 10, 2006
...to $1.34 million from $19 thousand in the prior-year quarter on license and royalty revenue from the company's two commercialized products, ProQuin and Glumetza ... - Trading Markets

Depomed Posts Wider Q1 Loss On Higher Operating Expenses - Quick ...  May 10, 2006
...million from $19 thousand in the same period of 2005, attributable to license and royalty revenue for its two commercialized products, ProQuin XR and Glumetza. ... - Trading Markets

Biovail Reports First-Quarter 2006 Financial Results; Company ...  May 11, 2006
Partially offsetting factors include the continued growth in Tiazac(R) XC, the November 2005 launch of Glumetza(TM), and initial sales from Wellbutrin(R) XL ... - Genetic Engineering News

Depomed Finalizes Phase III Clinical Trial Protocol for Gabapentin ...  May 10, 2006
In addition, regulatory applications for once daily Glumetza(TM) for the treatment of Type II diabetes have been approved in the US and Canada. ... - Genetic Engineering News

Dear Subscriber to TheStreet.com Stocks Under $10,  Apr 19, 2006
The company now has two FDA-approved drugs on the market already: Glumetza for diabetes and Proquin for urinary tract infections. ... - TheStreet.com (subscription)





Depomedn Says Diabetic Drug Glumetza Shows Controlled Glucose ...  11 Apr 2006
...(RTTNews) - Depomed, Inc. (DEPO | charts | news | PowerRating) revealed results of Phase III clinical trial of Glumetza for the treatment of Type II diabetes. ... - Trading Markets

Dear Subscriber to TheStreet.com Stocks Under $10,  11 Apr 2006
DepoMed (DEPO:Nasdaq) announced this morning that data from its Phase III trial for Glumetza, a treatment for diabetes, were published in the April 2006 issue ... - TheStreet.com (subscription)

Stocks Under $10 Weekly Summary  Apr 7, 2006
The company is on track to have two drugs on the market in 2006 -- Glumetza for diabetes and Proquin for urinary tract infections -- and should release phase ... - TheStreet.com (subscription)

DepoMed Up on Favorable Coverage Start  Mar 20, 2006
...from shingles. The company already makes diabetes drug Glumetza and urinary tract infection treatment ProQuin XR. The investment ... - Houston Chronicle

Depomed to Present at CIBC Annual Biotechnology and Specialty ...  Mar 30, 2006
In addition, regulatory applications for once daily Glumetza(TM) for the treatment of Type II diabetes have been approved in the US and Canada. ... - Genetic Engineering News

Deals, Diabetes and Specialty Drugs  Apr 3, 2006
...companies may value on 2010 potential. DepoMed's approved Glumetza is currently a strategic solution. We also recommend investors to ... - Barron's (subscription)

Depomed Reports 2005 Year End Financial Results; Significant ...  Mar 14, 2006
The decrease was primarily due to reduced expenses related to clinical trials and other activities to support the development of Glumetza(TM) and ProQuin XR. ... - Genetic Engineering News

Biovail Reports Fourth Quarter, Year-End 2005 Financial Results  Mar 23, 2006
Also contributing in the fourth quarter of 2005 was Glumetza(TM), a once-daily formulation of metformin that was launched to Canadian physicians by the BPC ... - PharmaLive.com

Stocks Under $10 Weekly Summary  Mar 24, 2006
DepoMed already has two Food and Drug Administration (FDA) approved products on the market -- Glumetza for diabetes and Proquin for urinary tract infections ... - TheStreet.com (subscription)

Stocks Under $10 Weekly Summary  Mar 10, 2006
We believe the stock's current sales potential does not fully reflect the value of the company's two FDA-approved drugs -- Glumetza for diabetes and Proquin ... - TheStreet.com (subscription)

Stocks Under $10 Weekly Summary  Mar 17, 2006
However, we believe 2006 will mark an important inflection point for the company, as its patented drugs Glumetza for diabetes and Proquin for urinary tract ... - TheStreet.com (subscription)



Stocks Under $10 Weekly Summary  Mar 3, 2006
The company has two FDA-approved drugs -- Glumetza for diabetes and Proquin for urinary tract infections -- on the market now that use its Gastric Retention (GR ... - TheStreet.com (subscription),

Stocks Under $10 Weekly Summary  Feb 24, 2006
Lastly, the company could soon announce a new partner for US distribution of diabetes treatment Glumetza, as its relationship with Biovail (BVF:NYSE) dissolved ... - TheStreet.com (subscription),

Stocks Under $10 Weekly Summary  Feb 10, 2006
DepoMed has two FDA-approved drugs -- Glumetza for diabetes and Proquin for urinary tract infections -- that will be meaningful revenue contributors in 2006 ... - TheStreet.com (subscription),

Stocks Under $10 Weekly Summary  Feb 3, 2006
We believe 2006 and 2007 will be strong financial years for DepoMed as its Proquin (for urinary tract infections) and Glumetza (for diabetes) products hit the ... - TheStreet.com (subscription)

Stocks Under $10 Weekly Summary  Jan 13, 2006
In addition, DepoMed already has two approved drugs on the market -- Glumetza for diabetes and Proquin XR for urinary tract infections -- and its generic ... - TheStreet.com (subscription)

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional